No Data
Press Release: Humacyte Board of Directors Strengthened With Addition of John P. Bamforth and Keith Anthony Jones
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage
Humacyte Is Maintained at Buy by BTIG
Humacyte Is Maintained at Buy by
Humacyte Price Target Raised to $11.00/Share From $8.00 by BTIG
Humacyte Price Target Raised to $11.00/Share From $8.00 by
MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Monday.Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply during Monday's session amid a rise Bitcoin.
(HUMA) - Analyzing Humacyte's Short Interest
Humacyte's (NYSE:HUMA) short percent of float has risen 58.68% since its last report. The company recently reported that it has 8.25 million shares sold short, which is 9.14% of all regular shares
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $11
BTIG analyst Ryan Zimmerman maintains $Humacyte(HUMA.US)$ with a buy rating, and adjusts the target price from $8 to $11.According to TipRanks data, the analyst has a success rate of 47.8% and a